Sickle Cell Disease Pathophysiology and Related Molecular and Biophysical Biomarkers
Hematology/Oncology Clinics of North America, ISSN: 0889-8588, Vol: 36, Issue: 6, Page: 1077-1095
2022
- 8Citations
- 37Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations8
- Citation Indexes8
- Captures37
- Readers37
- 37
- Mentions1
- News Mentions1
- 1
Most Recent News
New Findings from Emory University Describe Advances in Sickle Cell Anemia (Sickle Cell Disease Pathophysiology and Related Molecular and Biophysical Biomarkers)
2023 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Hematology Daily -- A new study on Hematologic Diseases and Conditions -
Review Description
One of the challenges in sickle cell disease is its clinical variability. Our ability to identify the complications that a patient is at risk for is limited by a lack of validated diagnostic and prognostic biomarkers. Clinical care is limited by a lack of diagnostics to capture the biological variability needed to precisely direct patient care. Many biomarkers have been proposed, but few validated. We must make a concerted effort as a field to rigorously test proposed biomarkers to improve outcomes for our patients.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0889858822000636; http://dx.doi.org/10.1016/j.hoc.2022.06.005; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85142254335&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36400532; https://linkinghub.elsevier.com/retrieve/pii/S0889858822000636; https://dx.doi.org/10.1016/j.hoc.2022.06.005
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know